# China Point of Care Molecular Diagnostics Market

> China Point-of-care Molecular Diagnostics Market Research Report: Size, Share, Trend Analysis By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Applications (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End-use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), and By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.28%
- **2024:** $ 468.58 Million
- **2025:** $ 507.38 Million
- **2035:** $ 1,124.1 Million
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Cepheid (US), Hologic (US), Qiagen (DE), BD (US), Luminex Corporation (US)

**Report ID:** MRFR/MED/49962-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-point-of-care-molecular-diagnostics-market-51720

---

## Market Summary

## **China****Point-of-care****Molecular Diagnostics Market Overview**

As per MRFR analysis, the China Point-of-care Molecular Diagnostics Market Size was estimated at 432.75 (USD Million) in 2023.The China Point-of-care Molecular Diagnostics Market is expected to grow from 750(USD Million) in 2024 to 1,500 (USD Million) by 2035. The China Point-of-care Molecular Diagnostics Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035).

**Key China****Point-of-care****Molecular Diagnostics Market Trends Highlighted**

The growing need for quick and precise diagnostic solutions, especially in light of the changing healthcare environment, is driving notable trends in the China Point of Care Molecular Diagnostics Market. Rapid diagnostics are now a top priority for healthcare facilities as a result of the COVID-19 pandemic's acceleration of point-of-care testing adoption.

By expanding access to cutting-edge diagnostic techniques in both urban and rural areas, the Chinese government is aggressively investing in healthcare technology and infrastructure, which is supporting the development of molecular diagnostics. This industry presents a number of opportunities, such as the growing emphasis on personalised medicine and the incidence of infectious diseases.

Molecular diagnostics can help with early detection and preventative healthcare, which is becoming more and more popular as people become more health conscious. Furthermore, the incorporation of machine learning and artificial intelligence into diagnostic platforms offers the potential for more precise and effective analysis, improving patient outcomes.

Current trends also emphasise partnerships between domestic and foreign businesses to create cutting-edge testing solutions that are suited to the requirements of the Chinese healthcare system. Furthermore, China's regulatory landscape is changing as the National Medical items Administration seeks to expedite the licensing procedures for novel diagnostic items in order to promote innovation.

As the government works to raise the standard of healthcare across the country, more emphasis is also being placed on quality control and standardisation. All things considered, these market factors and patterns point to a dynamic point-of-care molecular diagnostics environment in China, marked by strong public health reaction and technology breakthroughs.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China****Point-of-care****Molecular Diagnostics Market Drivers**

**Increasing Demand for Rapid Diagnostic Testing**

The demand for rapid diagnostic testing is surging in China, especially in response to the COVID-19 pandemic, which highlighted the importance of Point-of-care Molecular Diagnostics. According to the National Health Commission of the People's Republic of China, there was a significant increase in the installation of Point-of-care testing devices, with over 15% growth in 2020 alone.

Leading organizations such as Beijing Genomics Institute (BGI) have contributed to this trend by developing innovative, reliable molecular diagnostic tests that can provide results in hours rather than days.

This accelerating demand is due to the increasing need for early diagnosis and immediate treatment decisions, especially in infectious diseases, which aligns with the government's push for improved healthcare resources in rural and underserved areas.

Hence, the growth of rapid diagnostic testing is a key driver for the China Point-of-care Molecular Diagnostics Market, expected to continue as more patients seek out accessible healthcare solutions.

**Rising Prevalence of Infectious Diseases**

The prevalence of infectious diseases in China has been a significant driver of the Point-of-care Molecular Diagnostics Market. With over 1 million reported cases of infectious diseases like tuberculosis and hepatitis every year, the demand for rapid and effective diagnostic solutions is evident.

The Chinese Center for Disease Control and Prevention has reported a concerning rise in the incidence of these diseases, emphasizing the necessity for timely diagnosis to prevent outbreaks. Organizations such as the World Health Organization have also recognized the effective role that Point-of-care testing can play in managing these infectious diseases.

This leads to an increased investment in molecular diagnostic technologies targeted at improving patient outcomes and controlling the spread of infections, propelling the China Point-of-care Molecular Diagnostics Market forward.

**Advancements in Technology**

Advancements in technology are significantly influencing the growth of the China Point-of-care Molecular Diagnostics Market. The incorporation of artificial intelligence and machine learning in diagnostic devices has enhanced the accuracy and speed of test results.

For example, collaborations among major players like Siemens Healthineers and local Chinese biotech firms are fostering innovations that streamline the diagnostic process, making it faster and more reliable.

As per China’s Ministry of Science and Technology, investments in healthcare technology reached approximately 20 billion USD in recent years, reflecting a strong commitment to upgrading healthcare infrastructure.

These technological advancements reduce costs and improve accessibility of testing, thereby supporting the ongoing evolution and expansion of the Point-of-care Molecular Diagnostics sector across China.

**Government Initiatives and Support**

Government initiatives in China are a major driving force for the Point-of-care Molecular Diagnostics Market. The government's 13th Five-Year Plan emphasizes the importance of enhancing disease prevention and control measures, with specific investments targeted toward molecular diagnostics.

Funding for healthcare innovation has seen a 30% increase year-on-year as China aims to integrate advanced medical technologies into routine practice. Initiatives like the 'Healthy China 2030' program aim to strengthen public health systems and improve patient access to essential diagnostics.

This supportive environment fosters a robust market for Point-of-care Molecular Diagnostics, creating opportunities for local and international firms to invest and innovate within the China Point-of-care Molecular Diagnostics Market.

**China****Point-of-care****Molecular Diagnostics Market Segment Insights**

**Point-of-care****Molecular Diagnostics Market Product Type Insights**

The China Point-of-care Molecular Diagnostics Market under the Product Type segment showcases a broad array of diagnostic tools that are essential in healthcare. Among these, PCR Tests are recognized for their critical role in detecting various infectious diseases, as they offer rapid results crucial for decision-making in clinical settings.

Nucleic Acid Amplification Tests have gained significant traction, particularly due to their accuracy and efficiency in diagnosing diseases at earlier stages, which is vital in a fast-paced healthcare environment.

Microarray technology provides high-throughput analysis capabilities, enabling simultaneous examination of numerous genetic markers, thereby empowering personalized medicine and targeted therapies. Next-Generation Sequencing stands out for its transformative capabilities in genomics, allowing for comprehensive genome analysis that drives advancements in precision medicine.

Other Genetic Tests encompass a variety of methodologies that continue to innovate within the realm of molecular diagnostics, addressing a spectrum of conditions and expanding the potential for early detection and intervention strategies.

The evolving landscape of these technologies is supported by a robust healthcare infrastructure in China that emphasizes high-quality medical services, reflecting the country's commitment to integrating advanced diagnostic solutions into routine healthcare.

As competition among various product types intensifies, the continuous improvement in design, accuracy, and cost-effectiveness of these tests underscores their importance in the overall dynamics of the Point-of-care Molecular Diagnostics Market.

The growing awareness and adoption of these diagnostic tools among healthcare professionals and patients further solidify their pivotal roles in enhancing healthcare outcomes across the nation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Point-of-care****Molecular Diagnostics Market Application Insights**

The China Point-of-care Molecular Diagnostics Market is rapidly evolving, driven by the increasing demand for rapid and accurate diagnostic solutions across various applications. Among these applications, the testing for Infectious Diseases is particularly significant due to the heightened focus on public health and disease control measures, especially following recent global health crises.

Genetic Testing has also gained traction, reflecting the growing interest in personalized medicine and awareness regarding hereditary conditions. Cancer Diagnosis plays a critical role, as early detection via point-of-care solutions can notably improve treatment outcomes; this segment is essential in addressing the rising cancer incidence in the country.

Additionally, the diagnosis of Metabolic Disorders is becoming increasingly important as lifestyle-related health issues escalate. The industry is witnessing advancements in technology and growing investments in Research and Development, which are expanding the landscape of diagnostics available within these application areas.

Overall, the combination of increasing healthcare awareness, technological progress, and supportive government initiatives is propelling the growth of the China Point-of-care Molecular Diagnostics Market across these applications.

**Point-of-care****Molecular Diagnostics Market****End-use****Insights**

The China Point-of-care Molecular Diagnostics Market showcases a diverse End-use landscape that plays a crucial role in healthcare delivery. Hospitals lead the way with their emphasis on prompt diagnostics to enhance patient management and treatment outcomes.

They are increasingly adopting Point-of-care testing to facilitate immediate decision-making in critical care scenarios. Diagnostic Laboratories are pivotal as well, enhancing their capabilities through advanced molecular diagnostic platforms that support a wide range of testing applications, thus promoting accurate disease detection and monitoring.

Home Care Settings are witnessing growth due to rising patient preference for convenience and rapid testing solutions, allowing individuals to perform tests in the comfort of their homes while reducing the burden on clinical facilities.

Outpatient Clinics complement this trend by integrating efficient diagnostic tools that streamline patient workflow and ensure timely results, thus improving overall healthcare efficiency.

The synergy among these End-uses drives innovation and adoption in the market, as they collectively contribute to enhancing healthcare outcomes in China, addressing demands for rapid, accurate, and accessible diagnostic solutions. As the healthcare landscape evolves, opportunities abound in leveraging these settings for enhanced patient care and improved diagnostic accuracy.

**Point-of-care****Molecular Diagnostics Market Technology Insights**

The China Point-of-care Molecular Diagnostics Market is evolving significantly within its Technology segment, driven by advancements in various methodologies. Isothermal Amplification has gained traction due to its ability to facilitate rapid testing without the need for thermal cycling, making it suitable for point-of-care settings.

Polymerase Chain Reaction remains a key player, renowned for its precision and efficiency in detecting nucleic acids, which is vital for disease identification and management. Sanger Sequencing, while more traditional, continues to be indispensable for its accuracy in genomic analysis, particularly in complex cases requiring detailed insights.

CRISPR Technology stands out for its revolutionary potential in therapeutic applications, providing enhanced specificity and versatility in gene editing. The convergence of these technologies not only broadens the diagnostic capabilities but also streamlines workflows, making them increasingly relevant in the fast-paced healthcare environment.

The ongoing modernization and regulatory support in China further accelerate the adoption of these technologies, catering to an expanding population's healthcare needs and enhancing overall public health responses.

**China****Point-of-care****Molecular Diagnostics Market Key Players and Competitive Insights**

The China Point-of-care Molecular Diagnostics Market has experienced significant growth due to increasing demand for rapid and accurate diagnostic solutions. This market is characterized by a range of competitors who are striving to establish their presence through innovative product offerings and strategic collaborations.

The competitive landscape is shaped by various factors including technological advancements, regulatory framework, and the evolving healthcare infrastructure within China. Companies are heavily investing in research and development to enhance their product portfolios, focusing on improving the efficiency, accuracy, and usability of their Point-of-care molecular diagnostic devices.

This growing emphasis on precision medicine entails not only a rise in industry participants but also a heightened level of competition where speed to market, pricing strategies, and customer service can be crucial differentiators.

Eiken Chemical has established a significant position in the China Point-of-care Molecular Diagnostics Market by leveraging its expertise in molecular testing and innovative product development. The company's strengths lie in its robust portfolio of diagnostic solutions that cater to various infectious diseases and conditions prevalent in the region.

Eiken Chemical has effectively integrated user-friendly features and rapid result turnaround into its products, making them a preferred choice among clinicians and healthcare professionals in China.

Their commitment to localized research and understanding the specific needs of the Chinese healthcare ecosystem has allowed them to build strong relationships with local healthcare providers, which in turn reinforces their market presence.

Additionally, Eiken Chemical's focus on quality control and regulatory compliance enhances its reputation in the competitive landscape, further strengthening its position in the market.

Qiagen has become a notable player in the China Point-of-care Molecular Diagnostics Market, distinguished by its broad array of diagnostic solutions and technologies designed to facilitate rapid and accurate testing. The company offers key products such as real-time PCR assays and sample preparation technologies, which are vital for both laboratories and Point-of-care settings.

Qiagen's strengths in the market include its extensive distribution network, strong brand recognition, and commitment to innovation, enabling it to deliver high-quality diagnostic solutions tailored to the needs of Chinese healthcare professionals.

The company's efforts to expand its operations in China have also been bolstered by strategic partnerships, collaborations, and mergers with local entities, enhancing its market reach and capabilities.

By focusing on technological advancements in molecular diagnostics, Qiagen maintains a competitive edge, ensuring that healthcare facilities can access reliable testing tools essential for effective patient management.

**Key Companies in the China****Point-of-care****Molecular Diagnostics Market Include:**

- Eiken Chemical
- Qiagen
- Thermo Fisher Scientific
- Roche
- BD
- GenePOC
- Siemens Healthineers
- PerkinElmer
- Ortho Clinical Diagnostics
- Grifols
- Mylab Discovery Solutions
- Cepheid
- DnaNudge
- Hologic
- Abbott

**China****Point-of-care****Molecular Diagnostics****Market****Developments**

Recent developments in the China Point-of-care Molecular Diagnostics Market have been marked by robust growth, attributed to the increasing demand for rapid and accurate diagnostic tools, especially during the COVID-19 pandemic. Companies such as Eiken Chemical, Qiagen, Thermo Fisher Scientific, Roche, and BD have expanded their portfolios to cater to this demand.

Notably, in June 2022, Cepheid launched a new molecular diagnostic test for a common respiratory pathogen, demonstrating the ongoing innovation in this sector. Additionally, in September 2023, Roche announced a partnership with a local firm to enhance diagnostic capabilities and production within China, reflecting a strategic focus on local market needs.

Mergers and acquisitions play a critical role, and in July 2023, Hologic acquired a small diagnostics company, emphasizing the trend towards consolidation in this competitive landscape. Growth in market valuation continues, driven by advancements in technology and regulatory support from the Chinese government, which has implemented measures to streamline approval processes for new diagnostic devices.

The market's potential remains significant, with expectations of continued investment in Research and Development and an evolving regulatory environment.

**China****Point-of-care****Molecular Diagnostics Market Segmentation Insights**

**Point-of-care Molecular Diagnostics Market Product Type Outlook**

- PCR Tests
- Nucleic Acid Amplification Tests
- Microarray
- Next-Generation Sequencing
- Other Genetic Tests

**Point-of-care Molecular Diagnostics Market Application Outlook**

- Infectious Diseases
- Genetic Testing
- Cancer Diagnosis
- Metabolic Disorders

**Point-of-care Molecular Diagnostics Market End-useOutlook**

- Hospitals
- Diagnostic Laboratories
- Home Care Settings
- Outpatient Clinics

**Point-of-care Molecular Diagnostics Market Technology Outlook**

- Isothermal Amplification
- Polymerase Chain Reaction
- Sanger Sequencing
- CRISPR Technology

## Market Drivers

### Increased Awareness and Education

There is a growing awareness and education regarding the benefits of molecular diagnostics among healthcare professionals and patients in China. This heightened understanding is driving demand for point-of-care testing solutions, as stakeholders recognize the advantages of rapid and accurate diagnostics. Educational campaigns and training programs are being implemented to inform healthcare providers about the latest advancements in molecular diagnostics. As a result, the point-of-care molecular diagnostics market is witnessing an uptick in adoption rates, with estimates suggesting a growth of approximately 10% in the coming years. This trend underscores the importance of knowledge dissemination in fostering a more informed healthcare environment.

### Government Initiatives and Funding

Government initiatives aimed at improving healthcare infrastructure in China significantly influence the point of-care-molecular-diagnostics market. The Chinese government has been actively investing in healthcare reforms, which include funding for advanced diagnostic technologies. This support is evident in various national health programs that prioritize the development and deployment of point-of-care testing solutions. For instance, the government allocated approximately $1 billion in 2025 to enhance diagnostic capabilities across the country. Such financial backing not only fosters innovation but also encourages local manufacturers to develop cost-effective solutions, thereby expanding the market reach of point-of-care-molecular-diagnostics.

### Rising Demand for Rapid Diagnostics

The increasing need for rapid diagnostic solutions in China is a key driver for the point of-care-molecular-diagnostics market. With a growing population and rising incidences of infectious diseases, healthcare providers are seeking efficient testing methods that can deliver results quickly. The demand for immediate diagnosis is particularly pronounced in rural and underserved areas, where access to traditional laboratory facilities is limited. This trend is reflected in the market, which is projected to grow at a CAGR of approximately 15% over the next five years. The ability to provide timely and accurate results not only enhances patient care but also reduces the burden on healthcare systems, thereby driving the expansion of the point of-care-molecular-diagnostics market in China.

### Growing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases in China serves as a significant driver for the point of-care-molecular-diagnostics market. Conditions such as diabetes, cardiovascular diseases, and respiratory disorders are becoming increasingly common, necessitating regular monitoring and timely interventions. The ability to conduct molecular diagnostics at the point of care allows for more effective management of these diseases, as patients can receive immediate feedback on their health status. This trend is expected to contribute to a market growth rate of around 12% annually, as healthcare providers seek to integrate point-of-care solutions into routine care practices to enhance patient outcomes.

### Technological Integration in Healthcare

The integration of advanced technologies such as artificial intelligence (AI) and machine learning into healthcare systems is transforming the point of-care-molecular-diagnostics market. In China, the adoption of these technologies is facilitating the development of more sophisticated diagnostic tools that can analyze data in real-time. This technological evolution not only improves the accuracy of tests but also streamlines workflows in clinical settings. As hospitals and clinics increasingly adopt these innovations, the market is likely to experience accelerated growth, with projections indicating a potential increase in market size by 20% over the next few years. The synergy between technology and diagnostics is reshaping the landscape of healthcare delivery.

## Future Outlook

The [Point of Care Molecular Diagnostics Market](https://www.marketresearchfuture.com/reports/point-of-care-molecular-diagnostics-market-11484) in China is projected to grow at an 8.28% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for rapid testing solutions.

**New opportunities:**

- Development of portable diagnostic devices for remote areas
- Integration of AI for enhanced diagnostic accuracy
- Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)services incorporating molecular testing

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Type: PCR Tests (Largest) vs. Nucleic Acid Amplification Tests (Fastest-Growing)

In the China point of-care-molecular-diagnostics market, PCR Tests hold a significant share, owing to their established reliability and rapid results. This segment is the largest, favored by healthcare providers for various diagnostic purposes, leading to dominance in both hospital and laboratory settings. Conversely, Nucleic Acid Amplification Tests are witnessing substantial growth, driven by advancements in technology and the increasing need for specific pathogen detection.

The growth trends in this segment reveal an upward trajectory for Nucleic Acid Amplification Tests, which are increasingly being adopted due to their high sensitivity and specificity. Factors such as rising infectious diseases and regulatory support further fuel this expansion. Meanwhile, the robust adoption of PCR Tests continues to sustain its market leadership, with innovations enhancing their efficiency and accessibility in patient care.

PCR Tests (Dominant) vs. Nucleic Acid Amplification Tests (Emerging)

PCR Tests are the dominant force in the China point of-care-molecular-diagnostics market, valued for their accuracy and speed in diagnosing a wide range of conditions. They are extensively used in acute and infectious disease settings, making them an essential tool for clinicians. On the other hand, Nucleic Acid Amplification Tests are emerging rapidly, offering enhanced capabilities in detecting genetic material with high precision. This segment is gaining traction due to its versatility in various applications, including oncology and infectious disease diagnostics, thus presenting a significant growth opportunity for manufacturers and stakeholders in the market.

### By Application: Infectious Diseases (Largest) vs. Cancer Diagnosis (Fastest-Growing)

In the China point of-care-molecular-diagnostics market, the 'Application' segment showcases a diverse distribution of demand across various applications. The segment is primarily led by Infectious Diseases, which commands a significant share due to the ongoing focus on rapid disease diagnosis and management. This is closely followed by Genetic Testing and Cancer Diagnosis, both of which are witnessing growing adoption as healthcare systems evolve and prioritize personalized medicine and early detection.

Growth trends in this segment are significantly influenced by technological advancements, regulatory support, and an increasing demand for rapid testing solutions. Infectious Diseases, propelled by outbreaks and pandemics, remains pivotal, while Cancer Diagnosis is emerging as the fastest-growing application due to heightened awareness and screening recommendations. The demand for innovative testing methods and increasing healthcare expenditure further augments the growth trajectory of these applications.

Infectious Diseases (Dominant) vs. Cancer Diagnosis (Emerging)

Infectious Diseases remain the dominant application in the China point of-care-molecular-diagnostics market, driven by urgent healthcare needs and advancements in diagnostic technologies. This application benefits from heightened public awareness of infectious diseases and their impact on health systems. On the other hand, Cancer Diagnosis is rapidly emerging as a vital component of this market. With increasing incidences of cancer and a growing focus on preventive healthcare measures, Cancer Diagnosis is becoming an essential part of clinical practices. Each application reflects distinct market dynamics, with Infectious Diseases focused on immediate response to health challenges, while Cancer Diagnosis hinges on proactive healthcare strategies and patient engagement.

### By End Use: Hospitals (Largest) vs. Home Care Settings (Fastest-Growing)

In the segment of end use for the China point-of-care molecular diagnostics market, hospitals hold the largest share due to their extensive infrastructure and demand for rapid diagnostics. Diagnostic laboratories follow closely, serving as critical facilities for accurate testing and analysis. Outpatient clinics and home care settings are gaining traction, appealing to patients seeking more accessible and convenient testing options.

The growth trends in this segment signal a shift towards an increasing preference for home care settings, which are becoming the fastest-growing area. This growth is driven by advancements in technology and a growing emphasis on patient-centered care. Additionally, COVID-19 has accelerated the demand for point-of-care testing solutions that allow for immediate diagnosis and treatment, particularly in home environments.

Hospitals: Dominant vs. Home Care Settings: Emerging

Hospitals are the dominant segment in the end use category, equipped with sophisticated technology and professionals skilled in molecular diagnostics. They provide comprehensive services but also rely heavily on efficient and timely diagnostic tools to manage patient care effectively. In contrast, home care settings represent an emerging segment, propelled by innovations in testing technologies that allow for effective diagnostics outside clinical environments. Patients increasingly prefer the convenience and comfort of home testing, supported by portable devices that provide rapid results. As patients seek more autonomy in their healthcare journey, the demand for home care diagnostics is set to rise, enhancing its appeal in the overall landscape of the market.

### By Technology: Polymerase Chain Reaction (Largest) vs. Isothermal Amplification (Fastest-Growing)

In the China point of-care-molecular-diagnostics market, the market share distribution reveals that Polymerase Chain Reaction (PCR) technology holds a significant portion of the market, primarily due to its established reliability and widespread use in diagnostics. Isothermal Amplification follows, gaining traction due to its ease of use and faster results, appealing to settings demanding rapid testing solutions.

Growth trends indicate that the Isothermal Amplification segment is rapidly gaining momentum as healthcare providers seek quicker diagnostic methods, aiding in timely clinical decisions. The increasing demand for rapid and accurate testing technologies, influenced by factors like the COVID-19 pandemic, has further propelled advancements in the segment, showcasing the importance of innovative solutions in diagnostics.

Technology: PCR (Dominant) vs. Isothermal Amplification (Emerging)

Polymerase Chain Reaction (PCR) is the dominant technology in the China point of-care-molecular-diagnostics market, characterized by its robustness and ability to amplify DNA, allowing for precise detection of various pathogens. In contrast, Isothermal Amplification, though emerging, has shown significant promise in recent years. This technique allows for DNA amplification at a constant temperature, eliminating the need for sophisticated thermal cycling equipment, which makes it ideal for use in remote or resource-limited settings. The growth of Isothermal Amplification resonates with increasing healthcare demands for rapid and efficient diagnostic tools, positioning it as a strong contender to complement PCR in the evolving diagnostic landscape.

## Competitive Benchmarking

The point-of-care molecular diagnostics market in China is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for rapid diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are strategically positioned to leverage innovation and regional expansion. Abbott Laboratories (US) focuses on enhancing its product portfolio through continuous innovation, while Roche Diagnostics (CH) emphasizes partnerships to strengthen its market presence. Thermo Fisher Scientific (US) is actively pursuing mergers and acquisitions to bolster its capabilities, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological differentiation and market responsiveness.
In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to emerge, yet the collective strength of major companies shapes the overall competitive dynamics, fostering an environment where innovation is paramount.
In October 2025, Roche Diagnostics (CH) announced a strategic partnership with a leading Chinese biotechnology firm to co-develop next-generation point-of-care testing solutions. This collaboration is expected to enhance Roche's capabilities in delivering rapid diagnostics tailored to local healthcare needs, thereby solidifying its market position. The strategic importance of this partnership lies in its potential to accelerate product development cycles and improve access to advanced diagnostic technologies in China.
In September 2025, Abbott Laboratories (US) launched a new molecular diagnostic platform specifically designed for the Chinese market, which integrates AI-driven analytics to enhance test accuracy and speed. This move not only demonstrates Abbott's commitment to innovation but also reflects a growing trend towards the integration of artificial intelligence in diagnostics. The introduction of this platform is likely to strengthen Abbott's competitive edge by addressing the unique demands of the Chinese healthcare landscape.
In August 2025, Thermo Fisher Scientific (US) completed the acquisition of a local diagnostics company, which is anticipated to expand its footprint in the Chinese market significantly. This acquisition aligns with Thermo Fisher's strategy to enhance its product offerings and streamline operations within the region. The strategic importance of this acquisition lies in its potential to provide Thermo Fisher with localized expertise and resources, thereby facilitating quicker responses to market demands.
As of November 2025, current trends in the point-of-care molecular diagnostics market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the evolving needs of the healthcare sector.

## Recent News & Developments

Recent developments in the China Point-of-care Molecular Diagnostics Market have been marked by robust growth, attributed to the increasing demand for rapid and accurate diagnostic tools, especially during the COVID-19 pandemic. Companies such as Eiken Chemical, Qiagen, Thermo Fisher Scientific, Roche, and BD have expanded their portfolios to cater to this demand.

Notably, in June 2022, Cepheid launched a new molecular diagnostic test for a common respiratory pathogen, demonstrating the ongoing innovation in this sector. Additionally, in September 2023, Roche announced a partnership with a local firm to enhance diagnostic capabilities and production within China, reflecting a strategic focus on local market needs.

Mergers and acquisitions play a critical role, and in July 2023, Hologic acquired a small diagnostics company, emphasizing the trend towards consolidation in this competitive landscape. Growth in market valuation continues, driven by advancements in technology and regulatory support from the Chinese government, which has implemented measures to streamline approval processes for new diagnostic devices.

The market's potential remains significant, with expectations of continued investment in Research and Development and an evolving regulatory environment.

**China****Point-of-care**

## Report Scope

| MARKET SIZE 2024 | 468.58(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 507.38(USD Million) |
| MARKET SIZE 2035 | 1124.1(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.28% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Cepheid (US), Hologic (US), Qiagen (DE), BD (US), Luminex Corporation (US) |
| Segments Covered | Type, Application, End Use, Technology |
| Key Market Opportunities | Integration of advanced technologies enhances accessibility and efficiency in the point of-care-molecular-diagnostics market. |
| Key Market Dynamics | Rising demand for rapid testing drives innovation and competition in the point-of-care molecular diagnostics market. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What is the current valuation of the point-of-care molecular diagnostics market in China?**
A: The market valuation was $468.58 Million in 2024.

**Q: What is the projected market size for point-of-care molecular diagnostics in China by 2035?**
A: The projected market size is $1124.1 Million by 2035.

**Q: What is the expected CAGR for the point-of-care molecular diagnostics market in China from 2025 to 2035?**
A: The expected CAGR during the forecast period is 8.28%.

**Q: Which companies are the key players in the China point-of-care molecular diagnostics market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Cepheid, Hologic, Qiagen, BD, and Luminex Corporation.

**Q: What were the valuations for PCR tests in the point-of-care molecular diagnostics market in 2024?**
A: The valuation for PCR tests was $100.0 Million in 2024 and is projected to reach $240.0 Million.

**Q: How does the market for cancer diagnosis applications in point-of-care molecular diagnostics compare to other applications?**
A: The cancer diagnosis application had a valuation of $150.0 Million in 2024, with a projected increase to $350.0 Million.

**Q: What was the market valuation for diagnostic laboratories in the point-of-care molecular diagnostics sector in 2024?**
A: The market valuation for diagnostic laboratories was $120.0 Million in 2024, expected to grow to $280.0 Million.

**Q: What are the projected valuations for CRISPR technology in the point-of-care molecular diagnostics market?**
A: CRISPR technology had a valuation of $182.58 Million in 2024, with projections reaching $464.1 Million.

**Q: Which segment of point-of-care molecular diagnostics is expected to see the highest growth from 2025 to 2035?**
A: The segment of cancer diagnosis is likely to see substantial growth, projected to reach $350.0 Million by 2035.

**Q: What was the valuation for home care settings in the point-of-care molecular diagnostics market in 2024?**
A: The valuation for home care settings was $80.0 Million in 2024, with expectations of growth to $200.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-point-of-care-molecular-diagnostics-market-51720*